Stay updated on Autologous TIL MDA-TIL in Recurrent Cancer Clinical Trial
Sign up to get notified when there's something new on the Autologous TIL MDA-TIL in Recurrent Cancer Clinical Trial page.
![Latest website image capture](/pages/_next/image?url=https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fvp-files-ore%2Fresources%2F12months%2F1_VQtDnmao5Ax30ZVw2ued2J-DU.uncropped.jpg&w=3840&q=75)
Latest updates to the Autologous TIL MDA-TIL in Recurrent Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check2 days agoNo Change Detected
- Check3 days agoNo Change Detected
- Check4 days agoChange DetectedThe website has been updated to version v2.10.0, adding 8 more conditions and 2 more interventions/treatments, while removing the previous version v2.9.7.SummaryDifference0.5%
- Check5 days agoNo Change Detected
- Check11 days agoChange DetectedThe website has been updated to Revision v2.9.7 from v2.9.6.SummaryDifference0.1%
- Check25 days agoChange DetectedThe value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent change in the version of the content on the webpage.SummaryDifference0.1%
- Check30 days agoChange DetectedThe value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent change in the version of the content on the webpage.SummaryDifference0.1%
- Check31 days agoChange DetectedThe value of Last Update Posted (Estimated) Revision has been updated from v2.9.1 to v2.9.3, indicating a revision in the information provided on the webpage.SummaryDifference0.1%
- Check32 days agoChange DetectedThe value of the web page has recently changed to show updated information about a phase II trial evaluating the efficacy of autologous tumor infiltrating lymphocytes MDA-TIL in treating patients with recurrent or refractory ovarian cancer, colorectal cancer, or pancreatic ductal adenocarcinoma. The study aims to assess various outcomes such as objective response rate, disease control rate, duration of response, progression-free survival, overall survival, and safety profile of the treatment.SummaryDifference41%
Stay in the know with updates to Autologous TIL MDA-TIL in Recurrent Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Autologous TIL MDA-TIL in Recurrent Cancer Clinical Trial page.